Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
The stock's fall snapped a four-day winning streak.
18hon MSN
We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going ...
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...
Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results